Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response

Eustachio Nettis,Silvia Ferrucci,Giovanni Pellacani,E. Di Leo,Giuseppe Argenziano,Caterina Foti,F. Rongioletti,Cataldo Patruno,Michela Ortoncelli,Luigi Macchia,Simona Tavecchio,L. Bonzano,Danilo Di Bona,G. Calabrese,Gabriella Fabbrocini

Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response

2021

Eustachio Nettis
Silvia Ferrucci
Giovanni Pellacani
E. Di Leo
Giuseppe Argenziano
Caterina Foti
F. Rongioletti
Cataldo Patruno
Michela Ortoncelli
Luigi Macchia
Simona Tavecchio
L. Bonzano
Danilo Di Bona
G. Calabrese
Gabriella Fabbrocini

Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified.

Keywords:

patient characteristics
Dermatology
Medicine
MEDLINE
Atopic dermatitis
treatment outcome
Dupilumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations